Hyperfine HYPR 深 沪
已收盘 11-06 16:00:00 美东时间
0.7195
+0.034
+4.98%
华盛通- 最 高0.741
- 今 开0.70
- 成交量 50.64万股
- 最 低 0.6802
- 昨 收 0.6854
- 总市值 7630.20万
- 52周最高 1.935
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 0.6674
- 委 比 98.76%
- 总股本 1.06亿
- 历史最高 16.61
- 量 比 0.73
- 振 幅 8.87%
- 历史最低 0.5327
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
10-28 12:30
Lucid Capital Markets Initiates Coverage On Hyperfine with Buy Rating, Announces Price Target of $2
Lucid Capital Markets analyst Alex Nowark initiates coverage on Hyperfine (NASDAQ:HYPR) with a Buy rating and announces Price Target of $2.
10-28 01:29
Full Transcript: Hyperfine Q2 2026 Earnings Call
Hyperfine (NASDAQ:HYPR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The...
10-12 17:24
Hyperfine shares are trading lower after the company reported its preliminary Q3 financial results and affirmed its FY26 sales guidance with its midpoint above estimates.
Hyperfine shares are trading lower after the company reported its preliminary Q3 financial results and affirmed its FY26 sales guidance with its midpoint above estimates.
10-08 21:02
Hyperfine expects Q3 revenue of $6M; shares jump 9%
Hyperfine (HYPR) announced Thursday that its preliminary, unaudited Q3 revenue is expected to be approximately $6.0 million versus a consensus of $5.13M, representing growth of 53% sequentially compar...
10-08 19:52
Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est
Hyperfine (NASDAQ:HYPR) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.
10-08 19:38
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target
BTIG analyst Marie Thibault reiterates Hyperfine (NASDAQ:HYPR) with a Buy and maintains $2 price target.
09-14 18:44
Hyperfine Receives FDA Clearance For Its Latest Optive AI Software Update; Plans Rollout Of New Software In The U.S. In September
This advancement is Hyperfine’s second FDA-cleared software package since the launch of its next-generation Swoop system in mid-2025. It builds on Hyperfine’s Optive AI software to deliver even higher image quality in challenging clinical environments, a more intuitive scanning experience for Swoop ...
08-20 20:17
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
